FilingReader Intelligence
Alembic Pharma reports 10% revenue growth in Q1
August 5, 2025 at 07:06 PM UTC•By FilingReader AI
Alembic Pharmaceuticals reported 10% revenue growth to INR 1,711 crore in Q1 FY26, with net profit rising 15% to INR 154 crore.
Growth was driven by a 21% increase in Ex-US International Generics and 13% growth in US Generics. The company's India Branded Business grew 5% to INR 599 crore.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Please find attached the Press Release.August 5, 2025 at 07:38 AM UTC
Please find attached the investor presentationAugust 5, 2025 at 07:41 AM UTC
Please find the unaudited financial Results for the quarter ended results 30th June, 2025.August 5, 2025 at 07:51 AM UTC
Submission of Audio Recording of Post Results Conference Call held on 5th August, 2025August 5, 2025 at 03:15 PM UTC
Please find attached the intimation for appointment of Statutory AuditorAugust 5, 2025 at 05:44 PM UTC
Please find the updated Contact details of KMP and senior officials pursuant to Reg 30 (5) of SEBI LODR Regulations, 2015.August 5, 2025 at 07:56 AM UTC
BSE:APLLTD•Bombay Stock Exchange
News Alerts
Get instant email alerts when ALEMBIC PHARMACEUTICALS publishes news
Free account required • Unsubscribe anytime